Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/06—Tripeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/07—Tetrapeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
  • A61K38/1816—Erythropoietin [EPO]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/20—Interleukins [IL]
  • A61K38/2013—IL-2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/21—Interferons [IFN]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/21—Interferons [IFN]
  • A61K38/212—IFN-alpha
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/21—Interferons [IFN]
  • A61K38/215—IFN-beta
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
  • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
  • C07K5/1002—Tetrapeptides with the first amino acid being neutral
  • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
  • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention relates to biological sciences, pharmacology, neurobiology, biotechnology and medical sciences, especially with Neurology and Internal Medicine. In general, it is related to the generation of therapies for the treatment of diseases of the central nervous system (CNS) that are or are the result of ischemic, inflammatory and / or neurodegenerative damage.
• CNS central nervous system
• the invention is based on the use of derivatives of C-Ficocianina (C-Fico) or part thereof, which have in their structure pyrophilic rings, for the treatment of cerebrovascular diseases, characterized by tissue hypoxia and diseases with inflammatory and neurodegenerative component . It also comprises the pharmaceutical combinations of said compounds with other biomolecules, which are administered both prophylactically and therapeutically.
• C-Fico C-Ficocianina
• Cerebral vascular accidents affect about 5% of the world's population over 65 and can cause serious physical disabilities in affected individuals (World Health Organization: Statistical Information System. World Health Organization, 2004). More than 90% of deaths occur in people over 50 years old and approximately 15% to 30% of patients who survive have some type of sequel (Buergo-Zuaznabar MA, et al. Electronic Journal of Medical Sciences in Cienfuegos : 2-22; Miranda QJ A. Cerebrovascular diseases, 2004; 1: 17-21; Rosamond W, et al. Circulation. 2007: 169-71).
• Neuroprotection is a prophylactic and therapeutic treatment strategy, whose main objective is to prevent the pathological neuronal loss that occurs in CNS diseases, for example in ischemia.
• Neuroregeneration has the fundamental objective of reversing the damage that occurs in neuroinflammatory and neurodegenerative diseases such as Multiple Sclerosis (MS).
• MS Multiple Sclerosis
• the main objectives in the treatment of cerebral ischemia are: (1) reduce the size of the ischemic zone and limit the possible extension of this area to the adjacent one; (2) limit the progressive advance of cell death to the recoverable area of penumbra within an appropriate therapeutic window (Muhammad S H A S. Eur Neurol. 2008; 59: 4-14).
• Candidates for new neuroprotective and / or neuroregenerative agents must block and / or attenuate cellular metabolic and biochemical processes that lead to progressive brain damage during and after the ischemic event. In addition, they should cover a broad spectrum of possible drug targets within the pathogenic mechanism of damage (Ovbiagele B, et al. Curr Treat Options Cardiovasc Med. 2003; 5: 441-449).
• Acute effects have been reported that are largely due to the anticholinergic effects of cannabinoids and include: dry mouth, eye redness and blurred vision, decreased blood pressure, increased heart rate, decreased reaction capacity, increased perceived sensations, loss of coordination and psychomotor slowdown.
• Chronic effects have also been reported such as: impaired immune system with a possible increase in the occurrence of cancer that exceeds, in the case of lung cancer, the probability of occurrence of this disease in tobacco smokers.
• Cannabis use during pregnancy can lead to cognitive and psychopathological alterations of children during adolescence.
• C-Fico is a biliprotein, found in some green-blue algae such as Spirulina platensis, which is frequently used as a dietary supplement in many countries and of which nutritional and cytoprotective properties have been very well argued (Bockow B I United States Patent No. 05709855 (1998); Kay, RA Crit. Rev. Food Sci. Nutr. 1991; 30: 555-573; González De RC, et al. Life Sci. 1993; 53: 57-61).
• C-Fico acts as an anticarcinogenic agent by inhibiting oxidative damage to deoxyribonucleic acid (DNA) mediated by ONOO- limiting tumor proliferation (Li B, et al. Biomed Pharmacother. 2005; 59: 551-60 ).
• this natural compound is an inhibitor of platelet aggregation (Hui-Fen Ch, et al. British Journal of Nutrition. 2006; 95: 435 ⁇ 40).
• C-Fico at a concentration of 1-3 mg / mL, prevents neuronal death caused by the absence of potassium and serum for 24 h in a culture of brain granular cells (Rimbau V, et al. Naunyn Schmiedebergs Arch Pharmacol. 2001 ; 364: 96-104).
• C-Fico activity was also examined in a rat brain damage model induced by kainic acid (Rimbau V, et al. Neuroscience Letters. 1999; 276: 75-78).
• the administration of a dose of 100 mg / kg of C-Fico reduced the signs and alterations evidenced in the treated animals with respect to the control group without treatment.
• C-Fico has been shown to inhibit COX-2 by: 1) the isolated enzyme test and (2) the complete blood test (Reddy CM, et al. Biochem. Biophys. Res. Commun. 2000; 277 : 599-603).
• Ficocianobilina is the chromophore of C-Fico, from the chemical point of view, it is characterized by the presence of pyrrolic rings without the protein fragment.
• Interferons were initially discovered as soluble proteins with antiviral activity and can be classified into: IFNs type I (IFN alpha and beta) and type II (IFN ganma). Although alpha and beta IFNs are generally considered to use a common receptor complex, several reports suggest that there are differences in the abilities of alpha and beta IFNs to induce certain biological effects. These include preferential induction of an IFN-specific gene (Rani MRS, et al. J Biol Chem 1996, 271: 22878-22888; Platanias LC, et al. J Biol Chem 1994, 269: 17761-17784), inhibitory effects of different growth factors (Rosenblum MG, et al.
• IFNAR1 IFN alpha receptor 1
• IFN beta is one of the drugs approved by the U.S. Food and Drug Administration (FDA) for MS, there are reports that also reflect low efficacy and high dose dependence for achieve an effect (Zaragozá Garc ⁇ a F et al. Farm Hospit. 2002; 26: 294-301).
• FDA U.S. Food and Drug Administration
• IFN therapy patients may experience pseudo-flu reactions such as fever, myalgia, chills, and generally discomfort between 24 and 48 hours after each injection. Necrosis at the injection site occurs in 5% of patients.
• IL-2 lnterleukin-2
• cTreg regulatory T cells
• IL-2 considered a modifier of the biological response, has been used in the treatment of cancer such as melanoma and renal cell carcinoma, as well as HIV.
• cancer such as melanoma and renal cell carcinoma, as well as HIV.
• the use of IL-2 has been tested in high dose regimens. In low doses the desired therapeutic effect is not always achieved.
• the high dose regimen involves the administration of this drug intravenously every eight hours, as long as the patient tolerates it, until 15 doses are reached.
• This regimen has significant side effects, which although in most cases are reversible when treatment is interrupted, due to the severity of some of them, patients are hospitalized and sometimes require intensive therapy care while receiving this drug.
• GHRP-6 Growth hormone Releasing Peptide-6
• This peptide which was originally described as an agent derived from intestinal metaencephalin, subsequently showed an unexpected growth hormone (GH) secretagogue effect in different mammalian species - including humans (Bowers CY, et al. Endocrinology. 1984 , 1 14: 1537-45; Pandya N, et al. J Clin Endocrinol Metab. 1998, 83: 1186-9).
• This molecule has been administered in humans intravenously, as a secretagogue agent for the differential clinical diagnosis of the different forms of dwarfism (Popovic V, et al. Lancet. 2000; 356: 1137-42).
• IGF-1 insulin-like growth factor 1
• IGF-1 insulin-like growth factor 1
• GHRP-6 reverses glutamate-induced cell death by decreasing the activation of caspases 7 and 9 (Delgado-Rub ⁇ n de Célix A, et al. J Neurochem 2006, 99: 839-49).
• Erythropoietin acts unspecifically on components of the "common final cascade" that determines the severity or progression in a large number of completely different brain diseases. EPO has anti-apoptotic, anti-inflammatory, antioxidant, neurotrophic, angiogenic and stem cell modulatory effects, so it could influence neural plasticity. Protective and regenerative properties of EPO have been reported, as well as the improvement of cognitive function in several animal models of neurological and psychiatric diseases. The "Góttingen-EPO-stroke trial” provided the first promising evidence in humans for neuroprotective therapy in acute brain diseases. The treatment Experimental with EPO to improve cognitive function in patients with schizophrenia, represents a new strategy for chronic brain disease.
• EPO has hematopoietic functions in the brain and other organs, particularly during development. AsialoEPO or EPO with low sialic acid content has been identified as a neurotrophic and neuroprotective agent in a wide variety of experimental contexts, from neuronal cell cultures to in vivo models of brain damage.
• AsialoEPO may be a new strategy for a wide variety of CNS disorders in adults and children, especially as a possible alternative for perinatal asphyxiation (S Juul. (2002) Acta Paediatrica 91 s438: 36-42) .
• Ischemic infarction is associated with a variety of pathophysiological changes that affect neuronal and glial brain tissue. These changes translate into the release of specific proteins to peripheral blood. Neuron-specific enolasa protein, S100B protein and glial fibrillary specific protein are possible markers of post-infarction brain damage in humans.
• EPO and AsialoEPO proteins have been used in the treatment of cerebral ischemia and neurodegenerative diseases, adverse effects associated with their use have also been reported. EPO therapy and increased hematocrit are associated with adverse effects such as hypertension and thrombosis. In these cases, the use of combinations of drugs that show greater efficacy is also justified, which could lead to the use of lower doses, other routes of administration and reduction of adverse effects.
• FCB-aa chromogenic peptides
• the chromogenic or FCB-aa peptides of the invention consist of sequences of between 3-6 amino acids of the alpha ( ⁇ -C-Fico) and beta ( ⁇ -C-Fico) chains of C-Fico, obtained by enzymatic digestion of the same.
• SEQ ID NO. 1 79 MAABLR 84 ( ⁇ -C-Fico);
• SEQ ID NO. 2 84 BAR 86 (BC-Fico);
• SEQ ID NO. 3 80 AABLR 84 ( ⁇ -C-Fico);
• B in bold is a cysteine that has covalently bound phycocyanobilin (FCB).
• the subject of the present invention is also a pharmaceutical composition comprising at least one peptide identified as SEQ ID NO. 1-5 and pharmaceutically acceptable excipients.
• a novelty of the invention consists in demonstrating a superior neuroprotective and neuro-regenerating effect of chromogenic peptides and FCB, compared to C-Fico, by showing protection from sodium glutamate-induced damage, a mechanism that mimics cerebral ischemia, in the line PC12 cell and in animal models of cerebral ischemia and MS.
• FCB-aa and FCB peptides showed protection at 25 times lower molar concentrations for FCB-aa and 10 times lower for FCB (2 ⁇ of FCB-aa and 5 ⁇ of FCB protect 100% of the cells subjected to damage), while 50 ⁇ of C-Fico was needed to protect about 75% of the cells. Additionally, in a particular embodiment, a reduction in infarct volume was demonstrated in the cerebral L / R ischemia model in Gerbils of Mongolia, when the animals were treated with FCB-aa and FCB. The results demonstrate superior effectiveness for FCB-aa (49.2%) compared to FCB (43.1%).
• FCB-aa a compound selected from the group consisting of the peptides identified as SEQ ID NO. 1- SEQ ID NO. 5, referred to as abbreviated FCB-aa, and the FCB for the manufacture of a medicament for the prophylaxis or treatment of ischemia or tissue degeneration.
• said medicament is used in the prophylaxis or treatment of CNS diseases that present with ischemic, inflammatory or neurodegenerative damage.
• Another aspect of the invention is that it provides a method for the prophylaxis or treatment of ischemia or tissue degeneration characterized in that a pharmaceutical composition comprising a compound selected from the group consisting of the peptides identified as SEQ ID NO is administered. 1- SEQ ID NO. 5 and the FCB to a subject who needs it.
• the method of the invention is characterized in that ischemia or tissue degeneration causes CNS diseases that present with ischemic, inflammatory or neurodegenerative damage.
• the invention provides a pharmaceutical combination comprising a first component, selected from the group consisting of the peptides identified as SEQ ID NO. 1- SEQ ID NO. 5 and phycocyanobilin, and a second component, selected from the group consisting of Interferons of type I, which include Interferon alpha (IFN-a) and Interferon beta (IFN-b), lnterleukin-2 (IL-2), Erythropoietin (EPO), asialoEPO and the Human Growth Hormone Secretagogue Peptide (GHRP-6).
• a first component selected from the group consisting of the peptides identified as SEQ ID NO. 1- SEQ ID NO. 5 and phycocyanobilin
• a second component selected from the group consisting of Interferons of type I, which include Interferon alpha (IFN-a) and Interferon beta (IFN-b), lnterleukin-2 (IL-2), Erythropoietin (EPO),
• the synergistic effect of its active components referring to its neuroprotective and / or neuroregenerative properties, makes its use rational in cerebral ischemia of different origins and in neurodegenerative diseases such as MS (Multiple Sclerosis), Alzheimer's Disease, Amyotrophic Lateral Sclerosis , Spinocerebellar Ataxias, Huntington's Disease and Parkinson's Disease.
• MS Multiple Sclerosis
• Alzheimer's Disease Amyotrophic Lateral Sclerosis
• Spinocerebellar Ataxias Huntington's Disease and Parkinson's Disease.
• alpha and beta IFNs are from the family of type I interferons, and use a common receptor complex, a number of observations suggest that there are differences in the properties of alpha and beta IFNs to induce certain biological effects.
• the evaluation of the combination FCB-aa / IFN-a and FCB / IFN-a was performed in a prophylactic scheme in the Experimental Autoimmune Encephalomyelitis (EAE) model, demonstrating a synergistic effect of the aforementioned combinations with respect to independent active principles, in terms of preventing the development of the disease.
• EAE Experimental Autoimmune Encephalomyelitis
• the combinations FCB-aa and FCB were evaluated with IFN-a and with IFN-b compared with their independent active ingredients, administered at doses of 3,375 mg / kg of FCB-aa, 750 pg / kg of FCB and 500 ng / Kg for both interferons, showing an efficiency relative to a decrease in the volume of cerebral infarction of 83.3% and 89.3%, for combinations of IFN-a with FCB and FCB-aa, respectively; and 87.0% and 93.6%, for combinations of IFN-b with FCB and FCB-aa, respectively, superior to that of the active ingredients separately in the brain L / R model in Gerbils of Mongolia.
• the combinations FCB-aa / IFN-b and FCB / IFN-b were evaluated, where they were administered at a daily dose of 3,375 mg / Kg of FCB-aa / Kg, 750 Mg / Kg of FCB and 6 doses of 500 ng / Kg of IFN-b, showing an efficacy relative to a decrease in clinical symptoms superior to that of the active ingredients separately, in the EAE model, so that a therapeutic effect in the animal model of EAE was also demonstrated.
• FCB-aa / IFN-b and FCB / IFN-b were evaluated as a pharmaceutical combination administered by different routes (intraperitoneal, nasal, oral and rectal) in the EAE model, demonstrating a similar pharmacological effect referring to clinical signs.
• the compounds that form the said pharmaceutical combinations can be applied simultaneously or separately in the same individual in the course of a single treatment.
• the pharmaceutical combinations referred to in this invention may be for parenteral, nasal, oral and rectal administration; with an appropriate excipient for said routes.
• the effect of FCB-aa, FCB and IL-2 on cerebral ischemia was evaluated.
• FCB-aa / IL-2 and FCB / IL-2 had a synergistic effect in terms of reduction in the volume of cerebral infarction, compared to the independent active components (49.2% effective for FCB-aa, 43.1 % effectiveness for FCB, 25.8% for IL-2 and 84.3% for the combination FCB-aa / IL-2 and 74.5% for the combination FCB / IL-2) in the cerebral ischemia model in Gerbils of Mongolia.
• FCB / GHRP-6 were administered intraperitoneally in the animal brain l / R model in Gerbils of Mongolia. From the morphometric point of view a synergistic effect was observed in the combination, which had a value of 85% effectiveness; compared to 35.8% for FCB and 36.1% for GHRP-6).
• Another novelty of this invention consists in the synergistic effect related to the reduction of the infarct volume demonstrated for the FCB-aa / EPO and FCB-aa / asialoEPO combinations; with respect to the components separately (49.2% effectiveness of the FCB-aa, 36.9% of the EPO, 39.4% of the AsialoEPO, 87.7% of the FCB / EPO combination, 90.5% of the FCB / asialoEPO combination, 91.7% of the FCB-aa / EPO combination and 94.5% of the FCB-aa / asialoEPO combination).
• the above makes rational the use of such combinations in the treatment of CNS diseases that are or are the result of ischemic damage.
• the components that make up the therapeutic combination of the invention can be administered simultaneously or sequentially to the same individual in the course of a medical treatment.
• the use of the pharmaceutical combination comprising a first component, selected from the group consisting of the peptides identified as SEQ ID NO. 1- SEQ ID NO. 5 and phycocyanobilin, and a second component, selected from the group consisting of Interferons of type I, which includes Interferon alpha (IFN-a) and Interferon beta (IFN-b), lnterleukin-2 (IL-2), Erythropoietin (EPO), AsialoEPO and the Human Growth Hormone Secretagogue Peptide (GHRP-6), for the manufacture of a medicament for the prophylaxis or treatment of CNS diseases of ischemic, inflammatory or neurodegenerative origin.
• said Medication protects the damaged brain parenchyma as a result of acute or chronic diseases.
• the invention also encompasses a method for the prophylaxis or treatment of CNS diseases of ischemic, inflammatory or neurodegenerative origin characterized in that a pharmaceutical combination is administered comprising: a first component, selected from the group consisting of the peptides identified as SEQ ID NO. 1- SEQ ID NO. 5 and phycocyanobilin; and a second component, selected from the group consisting of Interferons of Type I which includes Interferon alpha (IFN-a) and Interferon beta (IFN-b), lnterleukin-2 (IL-2), Erythropoietin (EPO), AsialoEPO and the Human Growth Hormone Secretagogue Peptide (GHRP-6) to a subject in need.
• a pharmaceutical combination comprising: a first component, selected from the group consisting of the peptides identified as SEQ ID NO. 1- SEQ ID NO. 5 and phycocyanobilin; and a second component, selected from the group consisting of Interferons of
• Said method is characterized in that the components that form the combination can be administered simultaneously or sequentially to the same subject in the course of a medical treatment.
• said treatment is applied to cerebral ischemia of different origins, MS, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Spinocerebellar Ataxias, Huntington's Disease and Parkinson's Disease.
• FCB-aa Mass spectrometry characterization of the FCB obtained by methanolic treatment (A) and the chromogenic peptides obtained by trypsin digestion, defined together as FCB-aa, B: SEQ ID NO. one ; C: SEQ ID NO. 2; D: SEQ ID NO. 3-5.
• FIG. 3 Effect of therapeutic treatment with FCB-aa (peptides 1 to 5) on the volume of cerebral infarction, 24 h after transient occlusion (10 min) of the Common Carotid Arteries (ACC) in gerbils of Mongolia. Different letters indicate statistically significant differences, according to an ANOVA followed by the Newman-Keuls test of multiple comparisons, p ⁇ 0.05. Values are plotted as means ⁇ SEM
• FIG. 4 Effect of therapeutic treatment with FCB, FCB-aa (peptide 1), IFN-a and IFN-b and combinations FCB / IFN-a, FCB / IFN-b, FCB-aa / IFN-a and FCB -aa / IFN-b on the volume of cerebral infarction, 24 h after transient occlusion (10 min) of the ACC in gerbils of Mongolia.
• FCB FCB-aa (peptide 1), IFN-a and IFN-b and combinations FCB / IFN-a, FCB / IFN-b, FCB-aa / IFN-a and FCB -aa / IFN-b
• Different letters indicate the significant differences with respect to the l / R + saline group, p ⁇ 0.05. Values are plotted as means ⁇ E.E.M.
• A representative images (4x magnification) of the left hippocampus of falsely operated animals (sham), or treated with saline, or with FCB-aa (peptide 3) and GHRP-6 (6.25 pg / kg, intraperitoneally), or with FCB-aa (peptide 3) / GHRP-6 (maintaining the dose and the corresponding route of administration) for 30 min, 3, 6 and 12 h after the ischemic event.
• B bilateral cell count performed in the C2, CA3 and CA4 regions of both hippocampus for each experimental group. Different letters indicate the significant differences with respect to the l / R + saline group, * p ⁇ 0.05. Values are plotted as means ⁇ SEM Figure 9.
• FCB FCB-aa (peptide 4), EPO, asialoEPO, or their respective combinations FCB / EPO, FCB / asialoEPO, FCB-aa (peptide 4) / EPO and FCB-aa (peptide 5) / asialoEPO on the volume of cerebral infarction, 24 h after transient occlusion (10 min) of ACCs in Mongolian gerbiis.
• Different letters indicate the significant differences with respect to the l / R + saline group, p ⁇ 0.05. Values are plotted as means ⁇ SEM
• Example 1 Mass spectrometry of phycocyanobilin obtained by methanolic treatment (FCB) and chromogenic peptides (FCB-aa).
• Figure 1A shows the m / z 587.26 signal corresponding to the FCB chromophore, obtained by differential ultrafiltration of the C-Fico methanolic extract.
• Figures 1 B, C and D show the mass spectrometry of FCB-aa obtained by trypsin digestion of C-Fico.
• Example 2 Neuroprotective effect of C-Fico, FCB and FCB-aa on sodium glutamate-induced damage in the PC12 cell line.
• PC12 cells (1.5x10 4 cells / well) were pre-treated with C-Fico (25, 50 ⁇ 50) or FCB (0.5; 1; 5 ⁇ ) or FCB-aa (0.25; 1; 2 ⁇ ), for 24 h, and then subjected to co-incubation with 50 ⁇ of sodium glutamate together with the corresponding product (different doses) for 4 h.
• Cell viability was measured by the (3 - (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium (MTT) bromide method and the percentage with respect to the control was reported, as it is shown in Figure 2.
• FCB-aa peptide 1
• Example 3 Demonstration of the neuroprotective and / or neuroregenerative properties of FCB-aa peptides, through the reduction of the infarct volume, in the L / R model in Mongolian gerbiis.
• the animals were treated with saline solution or with a cumulative dose of FCB-aa peptides (3,375 mg / kg each), intraperitoneally for 30 min, 3, 6 and 12 h after the ischemic event.
• Vi volume of infarction of the group ischemic treated with the corresponding product
• Vl / R volume of infarction of the ischemic group treated with saline solution.
• FCB-aa chromogenic peptides
• Example 4 Effect of FCB / IFN-a, FCB-aa (peptide 1) / IFN-a, FCB / IFN-b and FCB-aa (peptide 1) / IFN-b combinations in the bilateral ischemia-reperfusion model in Gerbils.
• Example 5 Demonstration of the pharmacological effect of the combinations FCB / IFN-a and FCB-aa (peptide 1) / IFN-with respect to the independent active principles, referring to the clinical signs in the EAE model.
• FCB / IFN- a and FCB-aa offer protection between 85% and 100% of animals induced to develop EAE, respectively.
• Example 6 Demonstration of the pharmacological effect of the combinations FCB / IFN-b and FCB-aa (peptide 1) / IFN-b with respect to the independent active principles, referring to the clinical signs in the EAE model.
• AC ⁇ area under the curve of the group treated with the corresponding product;
• ACEAE area under the EAE group curve.
• FCB-aa (peptide 1) / IFN-b and FCB / IFN-b combinations, and their independent active ingredients, in prophylactic scheme in the EAE model
• Example 7 Demonstration of the therapeutic effect of the FCB-aa (peptide 1) / IFNb combination by different routes in the EAE model.
• mice treated with the FCB-aa combination (peptide
• IFN-b FCB-aa 3,375 mg / kg + 500 ng of IFN-b / Kg
• FCB-aa 3,375 mg / kg + 500 ng of IFN-b / Kg were divided into different groups, according to the route of administration: intraperitoneal, oral, nasal and rectal.
• the therapeutic scheme was followed for 15 consecutive days, from day 9 and until day 24 after immunization.
• the control group corresponds to healthy mice that received no treatment.
• the clinical evaluation was performed on day 27 after immunization.
• Example 8 Neuroprotective and / neuroregenerating effect of the combination FCB / IL-2 and FCB-aa (peptide 2) / IL-2 in the bilateral ischemia-reperfusion model in Gerbils.
• FCB saline
• FCB-aa peptide 2
• IL-2 100 ng / Kg, subcutaneously
• FCB / IL-2 and FCB-aa peptide
• Example 9 Therapeutic effect of the FCB / GHRP-6 combination, and its independent active ingredients, in the bilateral ischemia-reperfusion model in Gerbiis.
• FCB-aa peptide 3
• GHRP-6 GHRP-6
• FCB-aa peptide 3
• GHRP-6 GHRP-6
• FCB-aa peptide 3 / GHRP-
• Example 10 Therapeutic effect of the FCB / EPO, FCB-aa (peptide 4) / EPO, FCB / asialoEPO and FCB-aa (peptide 5) / asialoEPO combinations and their independent active ingredients in the Gerbiis bilateral L / R model .
• the animals were treated with saline (intraperitoneally) or with a cumulative dose of FCB (750 pg / kg, intraperitoneally), FCB-aa (peptide 4) 3,375 mg / kg, EPO (500 U / Kg, per intraperitoneally), asialoEPO (200 U / Kg, nasally) or with FCB / EPO or FCB-aa (peptide 4) / EPO, FCB / asialoEPO and FCB-aa (peptide 5) / asialoEPO (maintaining the dose and corresponding route of administration) for 30 min, 3, 6 and 12 h after the ischemic event.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Endocrinology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Vascular Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Psychology (AREA)
• Urology & Nephrology (AREA)
• Psychiatry (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Mycology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Alternative & Traditional Medicine (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=46614264

Family Applications (1)

Country Status (18)

Cited By (2)

Families Citing this family (4)

Citations (3)

Family Cites Families (4)

• 2011
  • 2011-07-01 CU CU2011000146A patent/CU23963B1/es unknown
• 2012
  • 2012-06-29 JP JP2014517444A patent/JP6023803B2/ja active Active
  • 2012-06-29 RU RU2014103246/04A patent/RU2569302C2/ru active
  • 2012-06-29 KR KR1020147002552A patent/KR101987978B1/ko active Active
  • 2012-06-29 SI SI201230756A patent/SI2733149T1/sl unknown
  • 2012-06-29 IN IN510CHN2014 patent/IN2014CN00510A/en unknown
  • 2012-06-29 US US14/127,369 patent/US9518085B2/en active Active
  • 2012-06-29 EP EP12743356.3A patent/EP2733149B9/en active Active
  • 2012-06-29 ES ES12743356.3T patent/ES2601887T3/es active Active
  • 2012-06-29 CN CN201280032375.5A patent/CN103649106B/zh active Active
  • 2012-06-29 BR BR112013033970-5A patent/BR112013033970B1/pt active IP Right Grant
  • 2012-06-29 CA CA2838496A patent/CA2838496C/en active Active
  • 2012-06-29 WO PCT/CU2012/000003 patent/WO2013004203A1/es not_active Ceased
  • 2012-06-29 MX MX2013015206A patent/MX345534B/es active IP Right Grant
  • 2012-06-29 AU AU2012280776A patent/AU2012280776B2/en active Active
  • 2012-06-29 DK DK12743356.3T patent/DK2733149T3/en active
  • 2012-07-02 AR ARP120102397A patent/AR087034A1/es unknown
• 2013
  • 2013-12-18 ZA ZA2013/09554A patent/ZA201309554B/en unknown
• 2016
  • 2016-11-10 US US15/348,451 patent/US20170119733A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (53)

Also Published As

Similar Documents

Legal Events